TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Enhancing the Amount of Physical Activity Carried Out by Overweight Children at Leisure Time

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* overweight/obese children~* age 5-18~* boys and girls~Exclusion Criteria:~* children with genetic obesity or obesity cased by a disease

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Pedometer with supervision (Type: ACTIVE_COMPARATOR): Participants will get pedometers to evaluate their daily PA. The sport center stuff will review the child weekly reports, guide the child, encourage him and supervise that the recommended PA level is achieved.
- Pedometer without supervision (Type: ACTIVE_COMPARATOR): Participants will get pedometers to evaluate their daily PA. The sport center stuff won't give any recommendation or supervision for PA level.
- Control group (Type: NO_INTERVENTION): Overweight \& obese children not participating in an intervention.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: ASCT for Relapsed APL After Molecular Remission

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Men or women between age 18-60 years old~* Acute promyelocytic leukemia after relapse with confirmed cytogenetics t(15;17) and molecular analysis (PML-RARalpha)~* Mobilized peripheral CD34+ over 2x106/kg with negative PML-RAR alpha confirmed by PCR~* European Cooperative Oncology Group performance status 0-3~* Serum bilirubin \< 1.5x the upper limit of normal (ULN)~* Serum alanine transaminase (ALT)/aspartate transaminase values \< 2.5 x ULN~* Subjects (or their legally acceptable representatives) must signed an informed consent document indicating that they understanding the purpose of and procedures required for the study and are willing to participate in the study~Exclusion Criteria:~* Woman of child bearing potential~* Serum creatinine \> 400 Micromol/l after initial resuscitation patients with previous Grade 2-4 peripheral neuropathy~* Uncontrolled diabetes (if receiving antidiabetic agents, subjects must be on a stable dose for at least 3 months before first dose of study drug)~* Uncontrolled or severe cardiovascular disease including myocardial infarction within 6 months of enrollment, uncontrolled angina, clinically significant pericardial disease, or III-IV heart failure~* Known allergy to idarubicin

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- ASCT in relapsed APL (Type: EXPERIMENTAL): autologous hematopoietic cell transplantation for patients with relapsed APL after achieving molecular remission

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Vital Capacity

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* consent form signature~* Men and women aged over or equal to 18 years old~* Medical examination before the research~* Negative results of tests of pregnancy for the women at age to procreate or taking an effective contraceptive~* Patients with neuromuscular pathologies without tracheostmy - Vital Capacity \< 80% of theoretical value~Exclusion Criteria:~* Refuse to participate at the research~* Patient under guardianship or under trusteeship~* pregnant Women~* Patients unable to cooperate~* Patients without a security social scheme (as beneficiary or bearer of rights)~* Usual contra-indications for an insufflation (haemoptise, recent pneumothorax, pulmonary emphysema, pleuresy, nausea, chronic obstructive pulmonary diseasee or asthma, recent lobectomy, intracranial hypertension, troubles of consciousness, unable to talk)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- measure of assisted vital capacity by mechanical insufflation (Type: OTHER): measure of assisted vital capacity by a mechanical insufflation/exsufflation

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: A Study Evaluating if Pridopidine is Safe, Efficacious, and Tolerable in Patients With Huntington's Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Pride HD completion within the last 6 months, including 2 week follow up period or patients who transitioned from the Open HART study or patients who complete future safety and efficacy clinical trials of pridopidine. In addition, patients who have already completed their defined study period under Open PRIDE HD global or local amendments and have discontinued treatment with pridopidine will be allowed to re enter the Open PRIDE HD study.~* Women of child bearing potential or male participants: Adequate contraception and birth control~* Good general health~  * other criteria apply, please contact the investigator for more information~Exclusion Criteria:~* Similar baseline criteria for ECG, vital signs, cardiovascular system, and renal function to PRIDE HD;~* Similar concomitant medication restrictions to PRIDE HD.~  * other criteria apply, please contact the investigator for more information

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Pridopidine (Type: EXPERIMENTAL): The mode of administration is oral. Capsules will be swallowed whole with water. One capsule should be taken in the morning and 1 in the afternoon, 7 to 10 hours after the morning dose. Study drug can be taken irrespective of meals.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Outcome of Old Patient With Articular With Articular Implant Infection

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* hospitalized in infectious diseases, surgery, post-emergency unit, or geriatrics,~* diagnosed with a hip or knee prosthesis infection in the previous month according to the SPILF criteria (2009)(1).~Exclusion Criteria:~* Above criteria not met,~* Patient refusal,~* Mild cognitive impairment or more significant.

- Gender: ALL
- Minimum Age: 75 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- follow-up visit at 6 months and 1 year after inclusion. (Type: OTHER): addition of a follow-up visit at 6 months and 1 year after inclusion. No treatment will be given specifically for this study. Other visits are part of the normal and usual rhythm of follow-up and evaluation of treatment in these patients

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Lenalidomide, Vorinostat and Dexamethasone in Relapsed Patients With Peripheral T-Cell Non-Hodgkin's Lymphoma (PTCL)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients with relapsed PTCL according to WHO criteria who have received max. two previous treatments for PTCL~* Age ≥ 18 years.~* Adequate bone marrow function i.e. absolute neutrophile count of \> 1000/µl and thrombocytes \> 75,000/µl.~* Alkaline phosphatase and transaminases ≤ 2,5 x upper limit of normal (ULN)~* Total bilirubin ≤ 2,5 x ULN~* Creatinine clearance ≥ 50 ml/min~* Female subjects of childbearing potential† must: Understand that the study medication could have an expected teratogenic risk and agree to use, and be able to comply with, effective contraception and agree to have a medically supervised pregnancy test~* Male subjects must agree to use condoms and agree not to donate semen~Exclusion Criteria:~* Prior history of malignancies, other than PTCL, unless the subject has been free of the disease for ≥ 3 years~* Prior allogeneic bone marrow transplant or plans to undergo autologous/ allogeneic bone marrow transplant within 4 weeks of the initiation of vorinostat administration~* Prior treatment with a HDAC inhibitor~* Prior treatment with Lenalidomide (patients previously treated with Thalidomide may be enrolled)~* Known history of Deep Vein Thrombosis (DVT) and/ or pulmonary embolism (PE)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Ancrod (Viprinex™) for the Treatment of Acute, Ischemic Stroke

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Acute, ischemic stroke with first symptoms within 6 hours of beginning treatment~* Baseline NIHSS \> 5~Exclusion Criteria:~* No intracranial, extravascular blood on CT~* Hypertension (systolic \> 185; diastolic \> 105)~* Baseline fibrinogen level \< 100 mg/dL~* Thrombocytopenia (\< 100,000 / mm3)~* Recent (\< 3 days) or anticipated (\< 5 days) use of a thrombolytic agent~* Recent (\< 14 days) or anticipated surgery

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Intravenous ancrod (Type: EXPERIMENTAL): Intravenous ancrod infused at a rate of 0.167 IU/kg/hr (0.6 mL/kg/hr) for 2 or 3 hours depending on the pretreatment fibrinogen level.
- Intravenous Placebo (Type: PLACEBO_COMPARATOR): Intravenous placebo at a rate of 0.6 mL/kg/hr for 2 or 3 hours depending on the pretreatment fibrinogen level.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Intravitreal Celecoxib for Chronic Uveitis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Chronic inflammation and/or macular edema despite maximal medical treatment Unable to tolerate corticosteroids due to side effects Aphakic or Pseudophakic subjects~Exclusion Criteria:~* 15 years or younger Have active ocular infection Pregnancy Phakic subjects

- Gender: ALL
- Minimum Age: 15 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Celecoxib (Type: EXPERIMENTAL): 1-4 mg intravitreal injection ofCelecoxib

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Topical CBD Cream for Degenerative Hallux Disorders

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with a new diagnosis of hallux rigidus or hallux valgus~* VAS pain score of 4 or higher~* Age \> 18 years~* The patient provides informed consent~Exclusion Criteria:~* A previous operative procedure to the first metatarsal for treatment of hallux valgus or hallux rigidus~* VAS pain score at presentation less than 4~* Concomitant hallux valgus and hallux rigidus on the ipsilateral side~* Allergy to CBD, Cannabidiolic acid (CBDa) or any other ingredient contained in the topical cream~* Pregnant patients

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Mg-CBDa cream (Type: ACTIVE_COMPARATOR): Subjects in this group will receive the active Mg-CBDa (magnesium-cannabidiolic acid) for topical treatment of hallux valgus or hallux rigidus.
- Placebo cream (Type: PLACEBO_COMPARATOR): Subjects in this group will receive the inactive CBD cream for topical treatment of hallux valgus or hallux rigidus. The ingredients of the placebo cream are: butyrospermum parkii (shea butter), caprylic/capric triglycerides medium-chain triglycerides (MCT oil), and food coloring to match the CBD oil. There will be 345 grams of shea butter and 62ml MCT oil per batch.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Global rEgistry on decongestioN Therapy Using Less invasivE UltraFiltration

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* ≥18 years~* Inpatient-treated patients with acute volume overload, preferably in association with cardiac decompensation with signs of incipient diuretic resistance (lack of increase in urine output despite significant escalation of diuretic therapy; e.g. ≥80 mg furosemide / 24 h or less than 1375 mL urine output/40 mg furosemide per 24 h or equivalent dose of other loop diuretics \[established clinically or from the medical history\])~* New York Association Functional Class (NYHA) III-IV at inclusion~* Systolic or diastolic cardiac dysfunction (HF-REF or HF-PEF)~* Adequate venous access (preferably peripheral arm vein) allowing a flow rate ≥ 60 mL / min~* Written consent to the use of data in the registry (where necessary, by a legal guardian).~Exclusion Criteria:~* Contraindication to anticoagulation (e.g. known heparin-induced thrombocytopenia, severe bleeding)~* Terminal renal failure (stage V, GFR \<15 mL)~* Cardiogenic shock, e.g. in association with acute coronary syndrome (ACS)~* Other diseases or factors that, in the study doctor's opinion, constitute a potential contraindication to ultrafiltration~* Pregnant women, women in labour, breast-feeding women or women of childbearing potential, who are without adequate contraception or are planning a family. NB: a pregnancy test is performed systematically in women of childbearing age and the patient is not included in the event of pregnancy (positive test). It is absolutely essential that women, who have a negative test and who are included in the study, have an effective contraception.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- periph. minimal invasive ultrafiltration (Type: None): Patients with volume overload receiving ultrafiltration

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: AO Multicenter Intervention Trial for Prevention of Surgical Site Infection

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* • Age \> 18 years~  * Recent fracture (\< 10 days) located in femur, tibia or humerus~    * Any type of open or closed fracture~   * Produced by high or low energy trauma~ * Primary fracture treatment with surgery and use of any of the following:~    * Intramedullary or extramedullary devices including cases in which a temporary external fixator is used~   * Joint replacement~ * Informed consent obtained (if required by local EC/IRB), i.e.:~    * Ability to understand the content of the patient information/ICF~   * Willingness and ability to participate in the clinical investigation according to the Clinical Investigation Plan (CIP)~   * Signed and dated EC/IRB approved written informed consent~Exclusion Criteria:~* Pathologic fracture secondary to tumors, infection or cysts~* Patients with an underlying chronic, bone and joint infection or prior history of a bone and joint infection~* Refracture and non-union~* Peri-implant fractures~* Patients with terminal illness~* Pregnancy or women planning to conceive within the study period~* Prisoner~* Participation in any other medical device or medicinal product study within the previous month that could influence the results of the present study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 100 Years
- Healthy Volunteers: f

Study Arms:
- pre-intervention (Type: NO_INTERVENTION): The number of SSI are collected in this phase. Patients with fractures are enrolled and their standard of care treatment is observed.
- post-intervention (Type: OTHER): Here the same observations are made as in the first arm, however this is after the hospital staff was thought the prevention measures (all by themselves approved) and enforced to be applied.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Internet Intervention to Improve Physical Activity in Early Knee Osteoarthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Have felt pain/discomfort in or around the knee during the previous year that lasted more than 28 separate or consecutive days.~* Are 50 years or older.~* Have not been physically active regularly (meaning, you have not participated in moderate intensity activities more than 90 minutes a week) in the past six months.~* Have access to the internet.~* Live in British Columbia.~Exclusion Criteria:~* Have physician diagnosis of rheumatoid arthritis, psoriatic arthritis, gout, ankylosing spondylitis, polymyalgia rheumatica, connective tissue diseases or fibromyalgia.~* Have a history of using disease-modifying anti-rheumatic drugs (DMARD) or gout medications.~* Have had total knee replacement surgery or currently being considered for.~* Have had any knee surgery within the past four months.~* Have had acute injury to the knee in the past six months.~* Have been using medication that may impair physical activity tolerance (e.g., beta blockers)~* Are at other risks from exercising as identified by the Physical Activity Readiness Questionnaire (PAR-Q)

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- OPEN Intervention Group (Type: EXPERIMENTAL): Intervention group participants will receive an email prompt to access the OPEN website every two weeks for the first three months, with a short message about the ongoing projects at the Arthritis Research Centre of Canada. The OPEN website will remain accessible throughout the study, but no further prompting emails will be sent after Month 3. In addition, they will receive an education pamphlet produced by The Arthritis Society containing information about osteoarthritis, physical activity and other treatments.
- Control Group (Type: NO_INTERVENTION): Control group participants will receive, by email, the same Arthritis Society pamphlet as the Intervention group. Participants will also receive, by email, the same short message about the ongoing projects at the Arthritis Research Centre of Canada, every two weeks for the first three months (i.e. the same schedule as the intervention group receiving the prompting email so that the number of contacts is equal in both groups), but without the prompting to use the OPEN website.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Adductor Canal Mid-thigh and Adductor Canal Distal Thigh: Is Cutaneous Sensory Blockade Similar Among Block Techniques?

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adults aged 18 years or older~* Individuals undergoing surgery of the medial foot, medial ankle, or medial leg for which the anesthetic plan includes an adductor canal nerve block~Exclusion Criteria:~1. Any known deficit of the ipsilateral lumbar nerve roots, ipsilateral lumbar plexus, ipsilateral femoral nerve, obturator nerve or saphenous nerve including diabetic peripheral neuropathy~2. Any local disorder of the skin or otherwise where blockade is to be performed~3. Body mass index \>50~4. American Society of Anesthesiologists (ASA) classification greater than 3~5. Allergy to amide local anesthetic medications~6. Pregnancy~7. Incarceration~8. Inability to understand study procedures including inability to understand the English language

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: t

Study Arms:
- Mid-Thigh Adductor Block (Type: EXPERIMENTAL): Subject will receive a mid-thigh adductor block method using ropivacaine (0.5%, 15 mL).
- Distal-Thigh Adductor Block (Type: ACTIVE_COMPARATOR): Subject will receive a distal-thigh adductor block method using ropivacaine (0.5%, 15 mL).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues